Theratechnologies Inc (THTX)

$THTX $TNON

$THTX Whats interesting now, with he FDA approval yesterday, is there is now time for another company to swoop in and make an unsolicited counter offer. I've been a part of a few of those instances. Then of course, Future Pak, parent of CB has the right to match. Depends on how good of a deal CB's $3.01 cash + $1.19 in CVRs actually is and if somebody thinks they can do better. You never know. Anything can happen in this sector.

$THTX hey Theratechnologies, you might want to remove the "investment" calculator from your website. No long term investor in your garbage company has made a cent.

$THTX i bet they announce after 8pm

$THTX Could be time to buy in again.

OS Therapies (NYSE-A: $OSTX) announced that the company held a successful Scientific Advice Meeting with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in July and submitted an Innovative Licensing and Access Pathway (ILAP) application to advance regulatory approval for OST-HER2 in preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/os-therapies-1. The MHRA recommended applying for Project Orbis when submitting for regulatory approval to align the UK’s Marketing Authorization Application process with the US FDA’s Biologics Licensing Application (BLA) Accelerated Approval Program. Project Orbis is an FDA-led global initiative that enables simultaneous submission and review of oncology products across multiple countries, potentially accelerating patient access to promising cancer treatments. Highlights from today’s news release include: - Positive feedback received from the UK MHRA Scientific Advice Meeting held in July 2025. - ILAP application submitted to begin UK regulatory approval process for OST-HER2. - European Medicines Agency rapporteur meeting scheduled for October 2025 to initiate EU-wide Marketing Authorization via the Centralized Procedure. Paul Romness, MPH, CEO of OS Therapies, remarked, “We are pleased with the outcome of our meeting with MHRA in the UK and are working to ensure that we provide FDA and MHRA everything they need to be able to rapidly approve OST-HER2 for metastatic osteosarcoma patients. We have officially begun the regulatory process in Europe as the next part of our regulatory strategy to bring this novel immunotherapy to osteosarcoma patients worldwide.” Read the full release at: https://ir.ostherapies.com/news-events/press-releases/detail/71/os-therapies-receives-positive-feedback-from-uk-mhra Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://www.ostherapies.com and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email [email protected]. Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/os-therapies-1 $THTX $CGTX

OS Therapies (NYSE-A: $OSTX) reported statistically significant positive 2-year overall survival results from an interim analysis of its Phase 2b trial of its off-the-shelf immunotherapy candidate OST-HER2 for preventing or delaying recurrent, fully resected, pulmonary metastatic osteosarcoma. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/os-therapies-1. The company also announced its NYSE American listing has been added to the Russell Microcap, Russell Microcap Value, and Russell Microcap Growth indexes. FTSE Russell determines membership for its Russell indexes based on objective, market-capitalization rankings, and style attributes. Investment managers and institutional investors widely use Russell indexes for index funds and as benchmarks for active investment strategies. Highlights from today’s news release include: - 66.6% of patients treated with OST-HER2 (18/27) reached 2-year overall survival versus 40% in historical controls (p = 0.0046). - The FDA issued a Biologics License Application (BLA) number for OST-HER2 ahead of the anticipated filing following the pending August 27, 2025, End of Phase 2 Meeting. - The company is working with the FDA to align metrics for Regenerative Medicine Advanced Therapy (RMAT) designation, Breakthrough Therapy Designation (BTD), and BLA through the Accelerated Approval pathway. Paul Romness, MPH, Chairman & CEO of OS Therapies, remarked, “We are seeking to bring this novel immunotherapy to market to improve the survival rates in pulmonary metastatic osteosarcoma, and today’s updated interim overall survival data continues to show a statistically significant benefit for OST-HER2-treated patients compared with control. We believe that continued statistically significant outperformance in overall survival of OST-HER2 treated patients compared with historical control, together with the statistically significant positive 12-month Event Free Survival data presented at MIB Factor in June 2025, will provide the necessary scientific and medical basis to support a BLA under the FDA’s Accelerated Approval Program.” Read the full release at: https://ir.ostherapies.com/news-events/press-releases/detail/72/os-therapies-announces-statistically-significant-positive Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://www.ostherapies.com and visit B2i Digital for updates. For investor-related questions, please see OS Therapies’ Investor Relations page or email [email protected]. Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/os-therapies-1 $THTX $CGTX

$THTX ready to pop

$THTX will be acquired by CB Biotech and expected to close 11/30/25. Weekly and Daily charts suggest this is a hold till then.

OS Therapies (NYSE-A: $OSTX) announced a series of clinical and regulatory milestones today. The company has secured an End-of-Phase 2 meeting with the U.S. Food and Drug Administration on 27 August 2025 to discuss a rolling Biologics License Application for its lead candidate, OST-HER2, in recurrent, pulmonary-metastatic osteosarcoma; it has also lined up parallel Scientific Advice meetings with the European Medicines Agency and the UK Medicines & Healthcare products Regulatory Agency to advance OST-HER2 through centralized EU and ILAP pathways. In addition, all patients in the Phase 1 study of OST-504 for second-line prostate cancer have completed treatment, with updated data expected later in 2025. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/os-therapies-1 The update highlights management’s plan to secure U.S. approval before the Rare Pediatric Disease Priority Review Voucher program sunsets, potentially generating non-dilutive capital from a future PRV sale to fund OST-HER2 commercialization and advance additional pipeline candidates. Highlights from the news release include: - FDA End-of-Phase 2 meeting for OST-HER2 set for 27 August 2025, with the goal of agreeing on a rolling BLA submission under Accelerated Approval. - Scientific Advice engagements secured with EMA and UK regulators, paving the way for EU centralized approval and UK Conditional Marketing Authorization via ILAP. - Phase 1 OST-504 prostate-cancer trial fully treated; clinical data expected in the second half of 2025. Paul Romness, MPH, Chairman & CEO of OS Therapies, noted, “We are making significant progress towards our primary objective of obtaining regulatory approval for OST-HER2 in recurrent, pulmonary metastatic osteosarcoma prior to the sunsetting of the rare pediatric disease priority review voucher (“PRV”) program. If successful, we expect to receive significant non-dilutive funding from the sale of the PRV which we would then be able to deploy in commercializing OST-HER2 osteosarcoma and other HER2 expressing cancers, as well as advance the other clinical candidates in our pipeline, including OST-504 in prostate cancer. We strongly believe in the promise of the listeria immunotherapy platform to help prevent and treat cancer, and intend to judiciously deploy our capital to focus on the OST-HER2 approval while advancing our other clinical programs without deploying significant capital or running other clinical studies while we wait for the OST-HER2 approval and related PRV sale.” Full release: https://ir.ostherapies.com/news-events/press-releases/detail/69/os-therapies-provides-clinical-global-regulatory-updates. Led by Paul Romness and an experienced executive team that includes Christopher Acevedo, Robert Petit, John Doll, and Gerald Commissiong, OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other cancers. Disclosure: The management of B2i Digital owns unrestricted shares of OSTX stock purchased in the open market. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/os-therapies-1. $THTX, $CGTX